Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasCellular TherapyHodgkin LymphomaIndolent LymphomasT-Cell and NK-Cell NeoplasmsTransplantationDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupCD20+ICD10C81.-C82.-C82.7C82.9C83.0C83.1C83.3C83.7C84.4C84.6C84.7C85.2C86.1C86.2C86.5C88.0-C91.0-C91.1-C94.7-MeSHLeukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, T-Cell, PeripheralPrecursor B-Cell Lymphoblastic Leukemia-LymphomaWaldenstrom MacroglobulinemiaSequenceEPCO(0.16/0.8/48), DLBCL, C1 (PID2486) -|- EPCO48, C2-3 (PID2487) -|- EPCO48, C4-9 (PID2488) -|- EPCO48, C10+ (PID2489)IXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)MOSU(1/2/60), B-NHL, C1 (PID2105) -|- C2 (PID2106) -|- C3+ (PID2107)R-ACVBP (RITU375/DOXO75/CYCL1200/VIND2/BLEO10/PRED60) ind., DLBCL A (PID340) -|- cons., B (PID341) -|- cons., C (PID342) -|- cons., D (PID343)R-CHOP 14 (RITU375/CYCL750/DOXO50/VNCR2/PRED100), DLBCL, C1-6 (PID112) -|- RITU375, C7-8 (PID1448)R-CHOP 14 smart (RITU375/CYCL750/DOXO50/VNCR2/PRED100), DLBCL, C1 (PID926) -|- C2 (PID929) -|- C3 (PID930) -|- C4 (PID929) -|- C5 (PID930) -|- C6 (PID929) -|- C7+ (PID75)R-ICE (RITU375/ETOP100/CRBP5/IFOS5), DLBCL, C1 (PID348) -|- C2+3 (PID349)STUDY - levelSTUDY OPTIMAL, Arm F-ASTUDY OPTIMAL, Arm F-BChemotherapyChemo-substanceBendamustineBleomycinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEpcoritamabEtoposideFludarabineGemcitabineIfosfamideMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNivolumabOxaliplatinPixantronPrednisoloneRituximabVincristineVincristine liposomalVindesineChemo-substanceBendamustineBleomycinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEpcoritamabEtoposideFludarabineGemcitabineIfosfamideMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNivolumabOxaliplatinPixantronPrednisoloneRituximabVincristineVincristine liposomalVindesineChemo-substanceBendamustineBleomycinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEpcoritamabEtoposideFludarabineGemcitabineIfosfamideMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNivolumabOxaliplatinPixantronPrednisoloneRituximabVincristineVincristine liposomalVindesineChemo-substanceBendamustineBleomycinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEpcoritamabEtoposideFludarabineGemcitabineIfosfamideMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNivolumabOxaliplatinPixantronPrednisoloneRituximabVincristineVincristine liposomalVindesineNo. Substances123456 RadiotherapySupportive therapySupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFolinic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PalonosetronParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFolinic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PalonosetronParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFolinic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PalonosetronParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFolinic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PalonosetronParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateNo. Substances134567891011Protocol classificationTherapy classificationalternativecurrent standardolder age and/or reduced general conditionstudy analogStudy protocol, currentIntensityDose intensifiedStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleThird line Therapy phaseConsolidationInductionPre-phaseReinductionSalvageTherapy intentioncurativedisease controlpalliativeRisksAlopeciaAnemia Hb below 8g/dlAstheniaBleedingCardiotoxicityCytokine Release SyndromeDiarrheaEdemaEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHeadacheHyperglycemiaHypertensionHypokalemiaHypophosphatemiaIncrease AminotransferasesInfectionsLymphopeniaNeuropathyNeurotoxicityNeutropeniaOral MucositisPainPneumoniaPyrexiaRenal FailureSepsisThrombocytopenia below 50 000/µlTumor Lysis Syndrome only studiesPublicationAuthorAydin SBudde LECoiffier 2002Davies AEl Gnaoui TGisselbrecht CHeld GHerbrecht RKirschey SLiu E Luminari SMartin APettengell RPeyrade FPfreundschuh MRodriguez MARécherSchmitz NTessoulin BThieblemont CVelasquez WSWeidmann EDiseaseAggr. B-NHL, Rezidiv oder therapierefraktäraggr. B-NHL incl. DLBCL, nach Rezidiv oder bei fehlendem CR unter Erstlinie mit CHOP, ECOG 0-1Aggr. B-NHL über 80 Jahre oder unter 80 mit KI gegen R-CHOP, ErstlinieAggr. oder de novo transf. B-NHL, Rezidiv - Drittlinie und höher, ECOG 0-2aggressive, CD 20+ B-NHL, 18-60 Jahre, Erstlinie, ECOG 0-3aggressive CD20+ B-NHL, 61-80 Jahre, ECOG 0-1Aggressives B-NHL, 61-80 Jahre, Erstlinie, ECOG 0-2B-NHL, refraktär oder rezidivierend, ohne Eignung zur HochdosistherapieB-NHL, rezidiviert oder therapierefraktär, CD19- positiv, Lymphodepletion vor CAR T-Zell TherapieB-Non-Hodgkin-Lymphom/Hodgkin LymphomCoiffier 2002: DLBCL, 60-80 Jahre, ECOG 0-2, Erstlinie , Cunningham 2013: DLBCL, ab 18 Jahren, ECOG 0-3, Erstlinie.DLBCL, Erstlinie, bis 59 JahreDLBCL, Rezidiv oder refraktär, mit mindestens einer anthrazyklinhaltigen VortherapieDLBCL, Stadium II - IV, CD20+, Erstlinie, ECOG 0-2DLBCL, über 80 Jahre, ECOG 0-2, ErstlinieDLBCL Stadium I-IV, älter als 60 Jahre, Erstlinie, ECOG 0-2Lymphom, rezidiviert oder therapierefraktärLymphom, Rezidiv oder refraktär, mit mindestens einer anthrazyklinhaltigen VortherapieNon-Hodgkin-Lymphom / Hodgkin Lymphomrezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2rezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2rezidiviertes oder refraktäres B-NHL, mindestens zwei vorherige systemische BehandlungenRezidiviertes und therapierefraktäres DLBCL, FL Grad 3b, mind. 2 Vortherapien, ECOG 0-2OriginAbteilung für Hämatologie, Universität Duisburg-Essen, DeutschlandCancer Research UK Centre, University of Southampton, UK, SABRINA StudieCity of Hope National Medical Center, Duarte, CADepartment of Clinical Hematology, Henri Mondor Hospital, Créteil, FrankreichDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Haematology, St George's Hospital, University of London, EnglandDepartment of Oncology and Hematology, Hôpital de Hautepierre, Strasbourg, France, PIX203 trialDSHNHL 2002-1DSHNHL 2009-1, OPTIMAL > 60Euro18-trial Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena Cancer Center, ItalyGEL/TAMO cooperative groupe, SpanienGerman High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL), RICOVER-60Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigatorsGroupe d'Etude des Lymphomes de l'Adulte (GELA) investigators LNH03-2BHopital Saint-Louis, Hemato-oncologie, Universite de Paris, Paris, FranceHopital Saint Louis, Paris, Frankreich, CORAL StudieHospices Civils de Lyon, Université Claude Bernard, FrankreichInternal Medicine I Saarland University Medical School, DSHNHL 2015-1Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Frankfurt am Main, DeutschlandNantes Medical University, Nantes, FranceSection of Lymphoma, M.D. Anderson Cancer Center, Houston, TXUniversity of Texas M.D. Anderson Cancer Center, HoustonUniversity of Texas M.D. Anderson Cancer Center, Houston, USAUniversitätsklinikum des Saarlandes, Homburg, SMARTE-R-CHOP-14 Trial, DSHNHLProtocols in Revision 48 protocols foundProtocols under revision.DHAC - Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, Non-Hodgkin Lymphoma / Hodgkin Lymphoma. (PID2346)Epcoritamab (0.16/0.8/48), diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID2486)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, cycle 10+ (PID2489)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, Cycle 2-3 (PID2487)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, cycle 4-9 (PID2488)ESHAP - Etoposide 40 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 375, Non-Hodgkin Lymphoma. (PID2348)Fludarabine 30 / Cyclophosphamide 300, B-non-Hodgkin Lymphoma, Lymphodepletion (PID2471)MINE (Ifosfamide 1.33 / Mitoxantrone 8 / Etoposide 65), B-non-Hodgkin Lymphoma. (PID2389)Mosunetuzumab (1/2/60), B-Non-Hodgkin Lymphoma, cycle 1 (PID2105)Mosunetuzumab 30, B-Non-Hodgkin Lymphoma, cycle 3+ (PID2107)Mosunetuzumab 60, B-Non-Hodgkin lymphoma, cycle 2 (PID2106)Pixantron 50, diffuse large B-non-Hodgkin Lymphoma (PID360)R- Benda - Rituximab 375 / Bendamustine 120, diffuse large B-non-Hodgkin Lymphoma (PID338)R- ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID348)R- ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, diffuse large B-non-Hodgkin Lymphoma, cycle 2+3 (PID349)R-ACVBP - Cytarabine 100 consolidation, diffuse large B-non-Hodgkin Lymphoma Part D (PID343)R-ACVBP - high-dose Methotrexate 3000, diffuse large B-non-Hodgkin Lymphoma, consolidation, part B (PID341)R-ACVBP - Rituximab 375 / Doxorubicin 75 / Cyclophosphamide 1200 / Vindesin 2 / Bleomycin 10 / Prednisolone 60, induction, diffuse large B-non-Hodgkin Lymphoma Part A (PID340)R-ACVBP - Rituximab 375 / Ifosfamide 1.5 / Etoposide 300 consolidation, diffuse large B-non-Hodgkin Lymphoma Part C (PID342)R-ASHAP - Rituximab 375 / Doxorubicin 10 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 375, diffuse large B-non-Hodgkin Lymphoma (PID359)R-CHOEP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Etoposide 100 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID722)R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 1-6 (PID112)R-CHOP 14 - Rituximab 375, diffuse large B-non-Hodgkin Lymphoma, cycle 7-8 (PID1448)R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID113)R-COMP 21 - Rituximab 375 / Cyclophosphamide 750 / Vincristine 2 / lip. doxorubicin 50 / Prednisolone 100, diffuse large B-cell lymphoma (PID125)R-CPOP 21 - Rituximab 375 / Cyclophosphamide 750 / Pixantron 88 / Vincristine 2 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID931)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006)R-DHAC - Rituximab 375 / Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, B-Non-Hodgkin's Lymphoma/Hodgkin's Lymphoma (PID2345)R-DHAP - Rituximab 375 / Cisplatin 100 / Cytarabine 2000 / Dexamethasone 40, diffuse large B-non-Hodgkin Lymphoma (PID350)R-ESHAP - Rituximab 375 / Etoposide 40 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 250, diffuse large B-non-Hodgkin Lymphoma (PID358)R-miniCHOP - Rituximab 375 / Cyclophosphamide 400 / Doxorubicin 25 / Vincristine 1 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID339)Rituximab 1400, single dose subcutaneous (PID310)Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, B-non-Hodgkin Lymphoma (PID354)SMARTE- R-CHOP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 2,4,6 (PID929)SMARTE- R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID926)SMARTE- R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 3.5 (PID930)SMARTE- R-CHOP 14 - Rituximab 375, diffuse large B-non-Hodgkin Lymphoma, cycle 7+ (PID75)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972)Study - Level - Nivolumab 3 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID968)Study - Level - Nivolumab 3 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 2+ (PID970)Study - Level - Nivolumab 3 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID967)Study - Level - Nivolumab 3 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 2+ (PID969)Study - Level - Nivolumab 3, diffuse large B-non-Hodgkin Lymphoma, consolidation (PID971)Study - Level - Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID973)Study - Level - Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 2+ (PID974)Study - OPTIMAL - Arm F-A, R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1124)Study - OPTIMAL - Arm F-B, R-CHLIP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine Liposomal 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1123)Vincristine 1 / Prednisolone 100, Pre-phase, diffuse large B-non-Hodgkin Lymphoma (PID69)